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Background-—Data on cardiovascular diseases (CVD) and cognitive decline are conflicting. Our objective was to investigate if CVD
is associated with an increased risk for cognitive decline and to examine whether hypertension, diabetes, or adiposity modify the
effect of CVD on cognitive functioning.
Methods and Results-—Prospective follow-up of 6455 cognitively intact, postmenopausal women aged 65 to 79 years old enrolled
in the Women’s Health Initiative Memory Study (WHIMS). CVD was determined by self-report. For cognitive decline, we assessed
the incidence of mild cognitive impairment (MCI) or probable dementia (PD) via modified mini-mental state examination (3 MS)
score, neurocognitive, and neuropsychiatric examinations. The median follow-up was 8.4 years. Women with CVD tended to be at
increased risk for cognitive decline compared with those free of CVD (hazard ratio [HR], 1.29; 95% CI: 1.00, 1.67). Women with
myocardial infarction or other vascular disease were at highest risk (HR, 2.10; 95% CI: 1.40, 3.15 or HR, 1.97; 95% CI: 1.34, 2.87).
Angina pectoris was moderately associated with cognitive decline (HR 1.45; 95% CI: 1.05, 2.01) whereas no significant
relationships were found for atrial fibrillation or heart failure. Hypertension and diabetes increased the risk for cognitive decline in
women without CVD. Diabetes tended to elevate the risk for MCI/PD in women with CVD. No significant trend was seen for
adiposity.
Conclusions-—CVD is associated with cognitive decline in elderly postmenopausal women. Hypertension and diabetes, but not
adiposity, are associated with a higher risk for cognitive decline. More research is warranted on the potential of CVD prevention for
preserving cognitive functioning. ( J Am Heart Assoc. 2013;2:e000369 doi: 10.1161/JAHA.113.000369)
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T he number of individuals suffering from cardiovasculardiseases has increased over the last few decades
making cardiovascular-related death the leading cause of
death in developed countries. Simultaneously, the number of
people affected by mild cognitive impairment or dementia has
been steadily growing with cognitive decline posing a
significant threat and health burden to aging individuals.1
Previous studies have examined the association between
atherosclerotic disease and the risk for developing dementia
or mild cognitive impairment.2,3 It is now widely accepted that
atherosclerosis is an important cause of many vascular
diseases that may also alter cognitive functioning by poten-
tially chronically lowering cerebral perfusion and by affecting
the neurovascular unit.4 Additionally, several population-
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ORIGINAL RESEARCH
based studies have provided ample evidence that cardiovas-
cular risk factors such as hypertension,5,6 diabetes,7,8 and
adiposity9–12 increase the likelihood for dementia. Neverthe-
less, findings on the relationship between the various sites of
atherosclerotic lesions and the risk for developing mild
cognitive impairment or dementia among older populations
have been controversial.2,3,13–18 Besides, other cardiac con-
ditions such as atrial fibrillation or heart failure are often the
consequence of underlying cardiovascular disease. Both
result in reduced cardiac output, increase the risk for
thromboembolism, and have been associated by some but
not all previous studies with cognitive decline.17,19–23
The objective of this study was to assess the association of
women with a history of myocardial infarction, angina
pectoris, atrial fibrillation, heart failure, other invasive vascular
procedures or diseases including coronary bypass surgery,
angioplasty, carotid endarterectomy, peripheral vascular dis-
ease or with a composite of any cardiovascular disease (CVD)
with the incidence of mild cognitive impairment (MCI) or
probable dementia (PD) later in life. Second, we examined the
effect of hypertension, diabetes, and adiposity on this
relationship.
Our study differs from previous reports as CVD was
defined broadly to investigate if a more general definition
adds more information on MCI/PD risk prediction. We also
apply extensive neurocognitive and neuropsychiatric examin-
ations for outcome ascertainment and provide additional data
on the effect of hypertension, diabetes, and adiposity on
cognitive decline.
Methods
Study Population
The study population consisted of 7479 postmenopausal
women enrolled in the Women’s Health Initiative Memory
Study (WHIMS), an ancillary study of the Women’s Health
Initiative Hormone Trials (WHI HTs).28,29 The WHIMS was
conducted to assess the relative effect of estrogen alone or in
combination with progestin on the incidence of probable
dementia and mild cognitive impairment.24–26 Recruitment
was initiated between May 1996 and December 1999 at 39
US clinical centers from women included in the WHI HTs who
were aged ≥65 and were free of dementia at enrollment.24–26
Details of the study population and of the initial screening
process have been reported previously.24–29 Participating
women were scheduled for in-clinic visits annually and were
sent semiannual questionnaires to ensure the timely update
of selected exposures and ascertain medical outcomes.30
Follow-up of this secondary analysis study was conducted
through February 2008 and the median follow-up was
8.6 years. All protocols were approved by institutional review
boards at participating institutions and all participants
provided written informed consent.
Exposure Assessment
Exposure status was derived from self-report questionnaires
at baseline.30 The composite variable of any CVD was coded
as positive if the participant reported a history of myocardial
infarction, angina pectoris, atrial fibrillation, heart failure,
peripheral vascular disease, coronary bypass surgery, angio-
plasty, or carotid endarterectomy at enrollment. Myocardial
infarction was defined as women with a reported history of
clinical myocardial infarction or evolving Q-wave myocardial
infarction.30 We excluded women with a history of stroke at
baseline from our analyses, as stroke is a known independent
cause and contributor of cognitive dysfunction.4 Moreover,
women with MCI at baseline or missing data were not
included in our analysis.
Outcome Assessment
As primary outcome measures for cognitive decline, we
assessed the incidence of MCI or PD (MCI/PD). Incident MCI
and PD cases were ascertained and centrally adjudicated in all
women enrolled in WHIMS.24–26 Specifically, the WHIMS
study was designed to detect probable dementia and mild
cognitive impairment in 4 phases.
First, the Modified Mini-Mental State Examination (3MSE)
was administered to all study participants as a cognitive
screening assessment at baseline and annually thereafter.
The 3MSE consisted of 15 items that were summed from 0 to
100, with higher scores reflecting better cognitive functioning.31
Women who scored below an education-adjusted cut point on
the 3MSE were further asked to continue with phase 2 and 3.
In phase 2, certified technicians administered a modified
Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) battery of neuropsychological tests and standardized
interviews to assess acquired cognitive and behavioral
impairments. Additionally, a designated informant (friend or
family member) was interviewed separately regarding
acquired cognitive and behavioral impairments in the partic-
ipant. In phase 3, women were seen by a local physician with
expertise in the field of dementia (ie, geriatrician, neurologist,
or geriatric psychiatrist). Using a standardized protocol
provided by the WHIMS Clinical Coordinating Center (CCC),
local physicians reviewed all available data (phases 1 and 2),
completed a structured medical history and performed a
clinical neuropsychiatric evaluation. The physician then clas-
sified the WHIMS participant as having no dementia, MCI, or
probable dementia, based on Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV) criteria. MCI was
operationally defined as being present if the participant
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showed poor performance (10th or lower percentile) in at
least one area of cognitive function based on the norms
established by the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD)32 or if a reliable informant
reported some functional impairment excluding a basic
activity of daily living, and no evidence of medical or
psychiatric disorders that could explain the decline in
cognitive function was ascertained and the absence of
adjudicated dementia was given.24–26 Women suspected of
having probable dementia underwent phase 4, including a
noncontrast computed tomography brain scan and laboratory
blood tests to rule out possible reversible causes of cognitive
decline. Finally, a physician was required to provide the most
probable etiology of dementia based on the DSM-IV criteria.
The WHIMS Clinical coordinating center adjudication com-
mittee (2 neurologists and 1 geriatric psychiatrist) indepen-
dently reviewed all probable dementia cases identified by the
local clinician, a random sample of 50% of MCI cases, and a
random sample of 10% of cases without dementia. Details of
this review have been published previously.24–26 Agreement
between local clinicians and adjudicators ranged between 75%
(j=0.60; 95% CI, 0.52 to 0.68) in the estrogen-alone trial and
77% in the estrogen plus progestin trial (j=0.63; 95% CI, 0.58
to 0.69). Results were not affected by treatment assignment
(P=0.49).27,33 In cases of disagreement, the diagnosis was
most frequently changed to a less serious classification (ie,
from probable dementia to MCI or from MCI to no dementia)
by the central adjudicators (64% to 74% of cases).27,33
Covariates
Information on all covariates was assessed via self-report or
by physical measure at baseline.30 Blood pressure was
measured by certified staff in the WHI clinic using standardi-
zed procedures.30 Hypertension was defined as a self-report
of current drug therapy for hypertension or clinic measure-
ment of SBP ≥140 mm Hg or DBP ≥90 mm Hg at enrollment.
Women were classified as having diabetes on the basis of self-
report of diabetes or self-report of diabetes treatment. Body
mass index (BMI) was calculated as weight in kg/height in m2.
Adiposity was defined as BMI ≥30. Physical activity was
assessed with metabolic equivalent tasks (in hours per week)
using a 10-item medical outcome scale.34 Waist circumfer-
ence at the natural waist or narrowest torso part and maximal
hip circumference were measured to the nearest 0.1 cm and
used to calculate the waist:hip ratio.
Statistical Analysis
The characteristics of women were compared according to the
presence or absence of any CVD at baseline. Differences
between women with and without CVD were compared using
v2 statistics for categorized covariates (Table 1). Incidence
rates (IR) of PD, MCI, or a composite per 1000 person-years
were calculated as the number of diagnosed cases of MCI or PD
(MCI/PD) occurring during the entire follow-up period of
WHIMS divided by person-years of follow-up (Tables 2 and 3).
For participants who did not develop MCI/PD, the follow-up
time was calculated from the date of baseline interview (ie,
study entry) to the date of the last follow-up cognition test. For
participants who developed MCI/PD, the follow-up time was
estimated as the entire time during which the subjects were
free of PD plus half of the follow-up time during which PD
developed.17 Hazard ratios (HRs) for the risk of MCI/PD
associated with the composite variable of CVD and its
subgroups myocardial infarction, angina, atrial fibrillation,
heart failure, coronary bypass surgery, angioplasty or carotid
endarterectomy, and peripheral vascular disease at baseline
were calculated using adjusted Cox proportional hazards
analyses (Tables 2 and 3). Two models were formed for each
outcome to examine the effect of potential confounding: Model
1 adjusted for WHI Hormone Trial Randomization assignment
(HTR arm), age at screening, race, education level, and baseline
3MSE (minimally adjusted model). Model 2 additionally
adjusted for smoking status, alcohol intake, physical activity,
sleep hours, diabetes status, hypercholesterolemia, hyperten-
sion status, BMI, waist–hip ratio, depression, and aspirin use
(fully adjusted model). The proportional hazards assumption
was tested for the composite variable of CVD and its subgroups
for each outcome (PD, MCI, MCI/PD) (Table 4). Thereafter, we
conducted additional sensitivity analyses for the effect of CVD
and its subgroups on cognitive decline by excluding incident
cases of stroke and TIA after baseline from our analysis
(Table 5). We also investigated the effect of myocardial
infarction on cognitive decline by excluding incident cases of
myocardial infarction after baseline from our analysis (data not
shown). Moreover, we conducted sensitivity analyses treating
death as a competing event. We defined death as a competing
Total Number of women (WHIMS Trial) (n =7,479)
Included in this study (n=7,278) Not included in this study (n=201):
H/x  of Stroke (n=123)
MCI at baseline (n=8)
Other reasons (n=70)
Complete Follow up (n=6,455) Missing Follow up Data (n=229)
Missing Exposure Information (n=154)
Missing Covariates (n=440)
Figure 1. Study inclusion. H/x of stroke indicates history of stroke;
MCI, mild cognitive impairment; WHIMS, Women’s Health Initiative
Memory Study.
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Table 1. Descriptive Characteristics of Postmenopausal
Women Enrolled in the Women’s Health Initiative Memory
Study by CVD at Baseline
Characteristic
CVD Absent,
n (%)
CVD Present,
n (%) P Value
Total 5560 (100.0) 895 (100.0)
Age at screening, y <0.0001
60 to 64 131 (2.4) 12 (1.3)
65 to 69 2739 (49.3) 348 (38.9)
70 to 74 1903 (34.2) 338 (37.8)
75 to 84 787 (14.2) 197 (22.0)
Ethnicity 0.0021
White (not of Hispanic
origin)
4919 (88.5) 772 (86.3)
Black or African American 335 (6.0) 81 (9.1)
Other 306 (5.5) 42 (4.7)
Education <0.0001
Less than high school 355 (6.4) 92 (10.3)
High school/Vocational or
training school
1934 (34.8) 315 (35.2)
Some college or associate
degree
1538 (27.7) 260 (29.1)
College and above 1733 (31.2) 228 (25.5)
Smoking 0.0455
Never smoked 3020 (54.3) 453 (50.6)
Past smoker 2174 (39.1) 389 (43.5)
Current smoker 366 (6.6) 53 (5.9)
Servings of alcohol per day <0.0001
None 2465 (44.3) 479 (53.5)
<1/day 2375 (42.7) 349 (39.0)
1 to 2/day 630 (11.3) 55 (6.2)
≥3/day 90 (1.6) 12 (1.3)
Physical activity (METs), h/week 0.0002
0 to 1.5 1334 (24.0) 243 (27.2)
>1.5 to 8 1579 (28.4) 296 (33.1)
>8 to 19 1516 (27.3) 211 (23.6)
>19 1131 (20.3) 145 (16.2)
Hours of sleep 0.0052
<6 2034 (36.6) 378 (42.2)
7 2053 (36.9) 316 (35.3)
8 1261 (22.7) 167 (18.7)
9 and above 212 (3.8) 34 (3.8)
Depression <0.0001
No 5171 (93.0) 785 (87.7)
Yes 389 (7.0) 110 (12.3)
Continued
Table 1. Continued
Characteristic
CVD Absent,
n (%)
CVD Present,
n (%) P Value
BMI, kg/m2 <0.0001
<25 1665 (30.0) 225 (25.1)
25 to 29 2032 (36.6) 291 (32.5)
>30 1863 (33.5) 379 (42.4)
Hypertension <0.0001
No 2954 (53.1) 319 (35.6)
Yes 2606 (46.9) 576 (64.4)
Use of aspirin <0.0001
No 4193 (75.4) 472 (52.7)
Yes 1367 (24.6) 423 (47.3)
Treatment for diabetes <0.0001
No 5282 (95.0) 779 (87.0)
Yes 278 (5.0) 116 (13.0)
Treatment for
hypercholesterolemia
<0.0001
No 4723 (85.0) 591 (66.0)
Yes 837 (15.0) 304 (34.0)
Waist–Hip ratio <0.0001
≤0.85 3615 (65.0) 515 (57.5)
>0.85 1945 (35.0) 380 (42.5)
WHI Clinical Trial
Randomization
Assignment
0.5479
Control arm 2806 (50.5) 442 (49.4)
Hormone trial arm 2754 (49.5) 453 (50.6)
Systolic BP, mm Hg <0.0001
<140 3986 (71.7) 580 (64.8)
≥140 1574 (28.3) 315 (35.2)
Diastolic BP, mm Hg 0.0303
<70 1845 (33.2) 330 (36.9)
≥70 3715 (66.8) 565 (63.1)
Diastolic BP, mm Hg 0.2456
<90 5314 (95.6) 863 (96.4)
≥90 246 (4.4) 32 (3.6)
BP control <0.0001
No treatment and BP
<140/90
2954 (53.1) 319 (35.6)
No treatment and BP
≥140/90
1064 (19.1) 121 (13.5)
Treatment and BP <140/90 812 (14.6) 229 (25.6)
Treatment and BP ≥140/90 730 (13.1) 226 (25.3)
BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular index; MET,
metabolic equivalent task; WHI, Women’s Health Initiative.
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event only if death occurred for a PD/MCI-free woman within a
year of the last cognitive examination, because the examina-
tion was performed annually. Finally, Cox proportional hazards
regression modeling with corresponding forest plots (Figure 2A
and 2B) was used to examine the interaction of selected risk
factors (hypertension, diabetes, adiposity) to the incidence of
MCI/PD. These analyses were based on the fully adjusted
models. All analyses were conducted using SAS statistical
software (version 9.3; SAS Institute Inc).
Results
Among the 7479 women in the WHIMS trial, 6455 with no
history of stroke, MCI and complete follow-up were included
in this study (Figure 1). The characteristics of women in our
sample at baseline examination are shown in Table 1. Among
the women included, 895 reported any CVD at baseline.
Those with CVD were older, more likely to be African-
American, had a higher BMI, were more likely to be a current
or past smoker and suffer from depression, whereas they
were less likely to have a higher education or be physically
active. Women affected by CVD also tended to be hyperten-
sive, under treatment for hypercholesterolemia or diabetes,
and more likely to use aspirin. Subjects who screened positive
for MCI or PD at follow-up were significantly older at baseline
in the CVD group compared with the non-CVD group (73.1
versus 71.8 years, P=0.0127) whereas the mean time until
diagnosis of MCI or PD was longer in women without CVD
(7.64 versus 6.95 years, P<0.0001).
The multivariate-adjusted HRs for incident MCI/PD related
to the composite variable of CVD and its various subgroups
(MI, angina pectoris, atrial fibrillation, congestive heart failure,
and other vascular diseases or procedures) are presented in
Tables 2 and 3. Corresponding test results for the proportional
hazards assumption for CVD and all subgroups can be found in
Table 4. IRs for MCI/PD were significantly higher among
women with any CVD (12.7/1000 person years) compared
with those without CVD (7.8/1000 person years). After full
adjustment the HRs for women with any CVD compared with
those free of CVD were 1.29 (95% CI: 1.00, 1.67) for MCI/PD.
Among women with myocardial infarction IRs for MCI/PD were
higher (20.0/1000 person years) compared with those
without myocardial infarction (8.1/1000 person years). This
rate corresponds to minimally adjusted HRs of 2.23 (95% CI:
1.51, 3.30). After full adjustment these associations remained
statistically significant with little change. Less markedly, rates
for angina pectoris were higher (14.6/1000 person years)
compared with those without angina pectoris (7.9/1000
person years); the minimally adjusted HR for MCI/PD was
moderately elevated with 1.66 (95% CI: 1.22, 2.25) and the
fully adjusted model with 1.45 (95% CI: 1.05, 2.01). The IRs of
MCI/PD in women with heart failure and atrial fibrillation were
18.7 and 11.9/1000 person years. The corresponding HRs did
not show any significant association with MCI/PD. Last, IRs
and HRs for MCI/PD were higher for women with any other
vascular disease and invasive procedure (17.3/1000 person
years and HR, 1.97; 95% CI: 1.34, 2.87) compared with those
without (8.0/1000 person years). Among the group of other
vascular diseases and invasive procedures coronary bypass
surgery (HR, 2.63; 95% CI: 1.46, 4.75), carotid endarterectomy
(HR, 3.03; 95% CI: 1.23, 7.47), and peripheral vascular disease
(HR, 1.82; 95% CI: 1.09, 3.02) were most strongly associated
with cognitive decline whereas no significant relationship was
found for women with angioplasty (HR, 1.67; 95% CI: 0.89,
3.13) (Table 3).
When we excluded women with incident stroke or TIA
events after baseline (Table 5), we found that a history of
myocardial infarction and angina remained strongly associ-
ated with cognitive decline (HR, 1.98; 95% CI: 1.29, 3.04 and
HR, 1.50; 95% CI: 1.07, 2.10). We also conducted a sensitivity
analysis by excluding incident cases of myocardial infarction
(n=134) and we found no substantial change of the results
(data not shown). Finally, when we conducted sensitivity
analyses treating death as a competing event, our results
were not materially changed (data not shown).
Interactions on the effect of hypertension, diabetes and
adiposity (BMI ≥30) on cognitive decline were examined in
women with or without CVD at baseline (Figure 2A and 2B). In
women without CVD, prevalent hypertension and diabetes
clearly increased the risk for MCI/PD (HR, 1.25; 95% CI: 1.00,
1.57; and HR, 1.83; 95% CI: 1.24, 2.70) (Figure 2A). Adiposity
Table 4. Test Results for Proportionality Hazards Assumption
in Cox Models (P Values Reported)
PD MCI PD or MCI
CVD* 0.0481 0.2218 0.4221
Myocardial infarction 0.3134 0.3249 0.2493
Angina pectoris 0.0835 0.4631 0.5119
Atrial fibrillation 0.4849 0.1149 0.2356
Congestive heart failure 0.6719 0.9808 0.8037
Other† 0.1522 0.3106 0.8043
Coronary bypass surgery 0.0878 0.9750 0.7234
Angioplasty 0.1989 0.6293 0.2034
Peripheral vascular disease 0.7606 0.4381 0.4586
Carotid endarterectomy 0.5550 0.0749 0.1146
CVD indicates cardiovascular disease; MCI, mild cognitive impairment; PD, probable
dementia.
*Composite of myocardial infarction, angina pectoris, atrial fibrillation, congestive heart
failure, coronary bypass surgery, angioplasty, carotid endarterectomy, and peripheral
vascular disease.
†
“Other” includes coronary bypass surgery, angioplasty, carotid endarterectomy, and
peripheral vascular disease.
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was not related to MCI/PD (HR, 0.84; 95% CI: 0.65, 1.08) in
this group. In women with CVD, the presence of diabetes
tended to increase women’s risk for cognitive decline but this
effect was not statistically significant (HR, 1.76; 95% CI: 0.90,
3.44) (Figure 2B). Similarly, no significant effect was found for
hypertension and adiposity in these women (HR, 0.99; 95% CI:
0.59, 1.64 and 0.81; 95% CI: 0.47, 1.39).
Discussion
In this large prospective study of 6455 cognitively intact
women aged ≥65 years CVD exclusive of stroke was found to
be associated with cognitive decline. Among CVD subgroups,
a history of myocardial infarction or other invasive vascular
procedures or diseases doubled the risk for cognitive decline.
These findings support the hypothesis linking clinically
manifest CVD to cognitive decline.
The underlying pathophysiological mechanisms by which
vascular diseases have been described to alter cognitive
functioning are complex: it is well known that cerebral
autoregulation keeps cerebral blood flow relatively constant
within a range of blood pressures to avoid interruption that
may lead to serious consequences, including brain dysfunction
and death.35,36 Simultaneously, neurons, glia, perivascular,
and vascular cells, systemically often termed as neurovascular
unit, work collectively to maintain homeostasis at the micro-
environmental level.4,37,38 Both systems, cerebral blood flow
control and neurovascular unit, are essential for protecting the
brain from unwanted swings in perfusion pressure and for
providing adequate neurovascular functioning.39 Various path-
ophysiological processes have been shown to target these
sensitive regulatory systems separately or in conjunction.
Vascular aging as reflected by the degree of atherosclerosis,
arteriosclerosis, and inflammation has emerged to provide the
underlying complementary mechanistic and pathophysiologi-
cal pathways between CVD and cognitive decline.35,36,40,41
Several studies with partly controversial findings have been
published on the associations between various sites and
degrees of atherosclerotic lesions or other surrogate markers
and the risk for cognitive decline.2,3,13–18,42 In the Rotterdam
study as well as the Cardiovascular Health Study Cohort a
relationship between preexisting CVD and dementia or
Alzheimer disease with highest risk for people suffering from
peripheral arterial disease or high common carotid wall
thickness has been described.3,15 On the other hand, using
autopsy data from the Baltimore Longitudinal Study of Aging,
Dolan et al noted that atherosclerosis and dementia were only
related to intracranial atherosclerosis, but not to cardiac or
aortic atherosclerosis.2 Most recently prospective findings on
the effect of coronary artery diseases on cognitive functioning
confirmed greater cognitive declines in affected participants.43
However, generalizability of these results may be limited as
only 74 patients suffered from vascular disease including 2
with a history of myocardial infarction. Our data on 209
postmenopausal women with a history of myocardial infarction
show that these women have double the risk of cognitive
decline history compared with their counterparts without
myocardial infarction. Additionally, we found high rates of
MCI/PD in those with angina pectoris, carotid endarterec-
tomy, peripheral vascular disease, and coronary bypass
surgery indicative of a relationship between cardiac and aortic
atherosclerosis and cognitive decline.
As cognitive decline and atherosclerosis share common
cardiovascular risk factors that have been shown to affect
cognitive functioning directly, we adjusted our findings
accordingly to several important confounding factors resulting
in little change in the magnitude of our associations.
Nonetheless, besides cerebral malperfusion cerebrovascular
events during the study period may provide an alternative
mechanism to explain our findings given the absence of
regular MRI neuroimaging of our study participants. In fact,
A
B
Figure 2. Hazard ratio (95%) of cognition event when CVD (A)
absent and (B) present. BMI indicates body mass index; CVD,
cardiovascular disease; MCI, mild cognitive impairment; PD, probable
dementia.
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multiple studies have reported a gradually progressive course
of cognitive decline in association with small, clinically silent
infarcts.27,33,44,45 On the other hand, the WHIMS trial was
rigorously designed with extensive neurocognitive and neuro-
psychiatric assessment to potentially identify cognitive
decline thereby reducing the possible role of cerebrovascular
events. Additionally, our sensitivity analyses confirmed a
robust association between myocardial infarction or angina
and cognitive decline after excluding women with incident
stroke and TIA during the study period. In contrast to previous
reports,17,23,46 we did not detect any statistically significant
relationship between atrial fibrillation or heart failure and
cognitive decline.
Among the many risk factors for cognitive decline, the
presence and the time of onset of hypertension, diabetes, or
adiposity may be key to the vascular modifications that affect
blood flow and cerebral metabolism.5,47 While several longi-
tudinal studies indicate that elevated blood pressure in midlife
increases the risk for cognitive decline in later life,48,49
studies on the effect of hypertension on dementia or cognitive
impairment occurring in later life are inconsistent.6 We found
hypertension to increase the risk for MCI/PD in elderly
women without clinical CVD but not in women suffering from
CVD most likely due to a limited number of events. Similarly,
the presence of diabetes increased the risk for MCI in women
without clinical CVD with no statistically significant findings
for PD or for women with CVD. These results are consistent
with morphological observations of the WHI Memory Study-
Magnetic Resonance Imaging (WHIMS-MRI) study where
participants with poorly controlled BP or diabetes had a
higher prevalence of abnormal white matter lesions of the
brain or smaller brain volumes with increased ischemic
lesions.50,51 Interestingly, adiposity tended to have a protec-
tive effect on cognitive decline in our study population. So far,
studies examining late-life BMI and dementia are sparse but
current evidence suggests that older persons with a high BMI
have less dementia risk than their counterparts with low
BMI.52,53 However, a recent meta-analysis showed that
underweight, overweight, or obesity in midlife increase
dementia risk.9
The strengths of our analysis include the sample size of
our study population, a prospective design with long follow-
up, confirmed and adjudicated assessment of MCI/PD, and
the availability of several confounding factors. Nevertheless,
our study also exhibits several limitations. Most importantly,
the presence of vascular disease, atrial fibrillation, and heart
failure was ascertained via self-report. However, validation
studies on the accuracy of self-reported data in WHI
subgroups have already shown good concordance with
medication inventories and medical history.54 Furthermore,
although a wide range of confounding factors was considered
in the analysis, residual confounding cannot be excluded. The
relatively low number of incident cases of MCI and PD may
have limited the power of our analyses. External validity may
be limited as our study population consisted only of relatively
healthy postmenopausal women, which may underestimate
the true association in the general population. Lastly, women
were selected for a more detailed cognitive assessment
based on a cut point on the 3MSE score. It may be that
individuals with CVD because of greater use of medications
as well as the effects of CVD scored below the cut point and
became at risk of further testing and to be diagnosed with
MCI or PD.
In conclusion, our findings suggest that CVD is associated
with cognitive decline in postmenopausal women. A history of
myocardial infarction doubled the risk for MCI or PD
compared with women without myocardial infarction. Hyper-
tension and diabetes, but not adiposity, are associated with a
higher risk for cognitive decline. These results add new
impetus to the contribution of vascular diseases and cardio-
vascular risk factors on cognitive functioning. As dementia is
an increasingly significant problem in developed countries,
more research is warranted on the potential of CVD
prevention for the preservation of cognitive health.
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